Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
COMPASS Pathways plc Market Cap
The COMPASS Pathways plc (CMPS) share price is expected to increase by 341.21% over the next year. This is based on calculating the average 12-month share price estimate provided by 10 stock analysts who have covered CMPS. Price targets range from $12 at the low end to $60 at the high end. The current analyst consensus for CMPS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 10 Wall Street analysts have assigned CMPS 10 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect COMPASS Pathways plc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CMPS. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CMPS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jason McCarthy Maxim Group | Buy | $12 | Maintains | Nov 1, 2024 |
| Leonid Timashev RBC Capital | Outperform | $18 | Maintains | Nov 1, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $60 | Maintains | Nov 1, 2024 |
| Leonid Timashev RBC Capital | Outperform | $23 | Reiterates | Sep 10, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | Reiterates | Sep 9, 2024 | |
| Patrick Trucchio HC Wainwright & Co. | Buy | $120 | Reiterates | Aug 23, 2024 |
| Sumant Kulkarni Canaccord Genuity | Buy | $48 | Maintains | Aug 2, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $120 | Reiterates | Jul 31, 2024 |
| Leonid Timashev RBC Capital | Outperform | $23 | Initiates | Jul 23, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | Reiterates | Jun 21, 2024 | |
| Patrick Trucchio HC Wainwright & Co. | Buy | $120 | Reiterates | May 13, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | Reiterates | Apr 30, 2024 | |
| Charles Duncan Cantor Fitzgerald | Overweight | Reiterates | Apr 19, 2024 | |
| Charles Duncan Cantor Fitzgerald | Overweight | Reiterates | Apr 18, 2024 | |
| Vikram Purohit Morgan Stanley | Overweight | $30 | Initiates | Apr 1, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $120 | Reiterates | Mar 1, 2024 |
| Neena Bitritto-Garg Deutsche Bank | Buy | $16 | Initiates | Dec 12, 2023 |
| Jonathan Fiore Cantor Fitzgerald | Overweight | $21 | Reiterates | Aug 22, 2023 |
| Sumant Kulkarni Canaccord Genuity | Buy | $50 | Maintains | Aug 22, 2023 |
| Jonathan Fiore Cantor Fitzgerald | Overweight | $21 | Reiterates | Aug 17, 2023 |
When did it IPO
2020
Staff Count
186
Country
United Kingdom
Sector/Industry
Healthcare/Medical Care Facilities
CEO
Mr. Kabir Kumar Nath M.A., M.B.A.
Market Cap
$307.2M
In 2023, CMPS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CMPS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Compass Pathways plc (Nasdaq: CMPS) will participate in the Evercore ISI HealthCONx Conference on December 3, 2024, and the Piper Sandler Healthcare Conference, hosting investor meetings.
Why It Matters - Compass Pathways' participation in key investor conferences may enhance visibility and attract interest, potentially impacting stock performance and investor sentiment in the biotech sector.
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Compass Pathways plc will present at the Stifel 2024 Healthcare Conference on November 19, 2024, at 10:55 am ET, focusing on innovations in mental health.
Why It Matters - Compass Pathways' presentation at a major healthcare conference can highlight its innovations and attract investor interest, potentially impacting stock performance and market perception.
Tue, 12 Nov 2024
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Analysts at Jefferies suggest that Robert F. Kennedy Jr.'s anticipated role in health policy under President-elect Trump may benefit the psychedelics sector, due to his supportive stance on the drug class.
Why It Matters - RFK Jr's potential influence on health policy could boost the psychedelic industry, attracting investment and driving innovation in mental health treatments.
Tue, 05 Nov 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - The health care sector has identified oversold stocks, indicating potential investment opportunities in undervalued companies.
Why It Matters - Oversold healthcare stocks indicate potential value buys, suggesting future price recoveries, which could lead to significant returns for investors who capitalize on this trend.
Fri, 01 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Compass Pathways plc reported positive phase 2b study results for COMP360 in treatment-resistant depression, meeting primary endpoints with a statistically significant p-value.
Why It Matters - Positive phase 2b results for COMP360 indicate potential market approval, enhancing Compass Pathways' growth prospects and attracting investor interest in the mental health treatment sector.
Thu, 31 Oct 2024
Sentiment - NEUTRAL
Source - The Motley Fool
Summary - Compass Pathways is in critical clinical trials, experiencing increased cash burn, but reported a net loss that was slightly narrower than anticipated.
Why It Matters - Narrower net loss amid increased cash burn indicates better-than-anticipated financial health for Compass Pathways, potentially boosting investor confidence during critical trial phases.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
